NAOV Quote, Financials, Valuation and Earnings

IRIDEX has a net margin of -243.42% compared to NanoVibronix's net margin of -14.17%. NanoVibronix's return on equity of -63.03% beat IRIDEX's return on equity of -218.69%.

NanoVibronix has a consensus price target of --, signalling upside risk potential of 81333.23%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 100.4%. Given that NanoVibronix has higher upside potential than IRIDEX, analysts believe NanoVibronix is more attractive than IRIDEX.

NanoVibronix has a beta of 2.036, which suggesting that the stock is 103.558% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.819%.

NanoVibronix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NanoVibronix pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

NanoVibronix quarterly revenues are $1M, which are smaller than IRIDEX quarterly revenues of $11.9M. NanoVibronix's net income of -$2.5M is lower than IRIDEX's net income of -$1.7M. Notably, NanoVibronix's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NanoVibronix is 0.15x versus 0.34x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

MaxCyte has a net margin of -243.42% compared to NanoVibronix's net margin of -98.76%. NanoVibronix's return on equity of -63.03% beat MaxCyte's return on equity of -19.59%.

NanoVibronix has a consensus price target of --, signalling upside risk potential of 81333.23%. On the other hand MaxCyte has an analysts' consensus of $7.00 which suggests that it could grow by 194.12%. Given that NanoVibronix has higher upside potential than MaxCyte, analysts believe NanoVibronix is more attractive than MaxCyte.

NanoVibronix has a beta of 2.036, which suggesting that the stock is 103.558% more volatile than S&P 500. In comparison MaxCyte has a beta of 0.358, suggesting its less volatile than the S&P 500 by 64.196%.

NanoVibronix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MaxCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NanoVibronix pays -- of its earnings as a dividend. MaxCyte pays out -- of its earnings as a dividend.

NanoVibronix quarterly revenues are $1M, which are smaller than MaxCyte quarterly revenues of $10.4M. NanoVibronix's net income of -$2.5M is higher than MaxCyte's net income of -$10.3M. Notably, NanoVibronix's price-to-earnings ratio is -- while MaxCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NanoVibronix is 0.15x versus 6.65x for MaxCyte. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -243.42% compared to NanoVibronix's net margin of -35.24%. NanoVibronix's return on equity of -63.03% beat Myomo's return on equity of -38.11%.

NanoVibronix has a consensus price target of --, signalling upside risk potential of 81333.23%. On the other hand Myomo has an analysts' consensus of $9.05 which suggests that it could grow by 204.71%. Given that NanoVibronix has higher upside potential than Myomo, analysts believe NanoVibronix is more attractive than Myomo.

NanoVibronix has a beta of 2.036, which suggesting that the stock is 103.558% more volatile than S&P 500. In comparison Myomo has a beta of 1.633, suggesting its more volatile than the S&P 500 by 63.336%.

NanoVibronix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NanoVibronix pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

NanoVibronix quarterly revenues are $1M, which are smaller than Myomo quarterly revenues of $9.8M. NanoVibronix's net income of -$2.5M is higher than Myomo's net income of -$3.5M. Notably, NanoVibronix's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NanoVibronix is 0.15x versus 2.99x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -243.42% compared to NanoVibronix's net margin of -77.93%. NanoVibronix's return on equity of -63.03% beat Stereotaxis's return on equity of -174.6%.

NanoVibronix has a consensus price target of --, signalling upside risk potential of 81333.23%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 111.27%. Given that NanoVibronix has higher upside potential than Stereotaxis, analysts believe NanoVibronix is more attractive than Stereotaxis.

NanoVibronix has a beta of 2.036, which suggesting that the stock is 103.558% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.088%.

NanoVibronix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NanoVibronix pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

NanoVibronix quarterly revenues are $1M, which are smaller than Stereotaxis quarterly revenues of $7.5M. NanoVibronix's net income of -$2.5M is higher than Stereotaxis's net income of -$5.8M. Notably, NanoVibronix's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NanoVibronix is 0.15x versus 6.68x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.